Company / Working Capital
Pfizer Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$5.9B
FY2025
5-year range
-$4.5B / $17.0B
FY2021-FY2025
Trend
-19.7%
vs FY2024
Sector context
#7 of 213
Health Care
What the data says
Among 213 Health Care companies, Pfizer is in the top 3% for working capital. Working Capital has fluctuated over the past 10 years, ranging from -$4.5B in FY2019 to $18.1B in FY2018.
Based on SEC 10-K filings.
$5.9B in FY2025 with a 5-year CAGR of -8.4%. Top quartile in the Health Care sector.
Improved from -$4.5B to $5.9B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -13.4%
- 5-Year CAGR
- -8.4%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 213This company $5.9B Sector average $934.6M
▼
+532.8% above sector average
Key checks
Key Insights
- 5-year CAGR of -8.4%, indicating a declining trend.
- In FY2025, working capital decreased 19.7% year-over-year.
- Ranks #7 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.9B | -19.7% |
| FY2024 | $7.4B | +265.1% |
| FY2023 | -$4.5B | -148.9% |
| FY2022 | $9.1B | -46.4% |
| FY2021 | $17.0B | +86.1% |
| FY2020 | $9.1B | +303.2% |
| FY2019 | -$4.5B | -124.9% |
| FY2018 | $18.1B | +68.6% |
| FY2017 | $10.7B | +36.8% |
| FY2016 | $7.8B | -45.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026